age ≥ 18 years.

consent and ability to complete a multiparametric MRI of the prostate.

consent and ability to complete PSMA PET/CT.

multiparametric MRI of the prostate with a PI-RADS score of 4 or 5 for suspicious lesions.

Positive PSMA PET/CT. Its positive is defined as a suspicious lesion score of 2 or 3 (see remarks for specific scoring criteria).

good physical condition with an ECOG score of 0 or 1.

no history of radiotherapy or other surgery to the pelvis

the presence of pelvic lymph node enlargement (\>2 cm) or metastasis is allowed; ≤5 bone and lymph node metastases are allowed

the patient has good cardiac, pulmonary, hepatic and renal function and is able to tolerate local treatment (surgery or external radiotherapy) of the primary site and metastases, and the treatment will not cause serious complications for the patient.

the patient participates voluntarily and has signed an informed consent form

the patient is able to receive treatment and subsequent follow-up

the expected survival time is greater than 1 year.

unwillingness or inability to perform multiparametric MRI of the prostate; or PI-RADS score of 0-3

request for prostate puncture biopsy.

unwillingness or inability to perform PSMA PET/CT; or PSMA PET/CT score of 0 or 1

refusing radical prostate cancer surgery, or choosing other primary lesion treatment modalities other than radical prostate cancer surgery

poor physical condition that prevents them from tolerating radical prostate cancer surgery

More than 5 bone and lymph node metastases, visceral metastases

history of combined other malignant tumors (except basal cell carcinoma of the skin or other tumors that have been cured for more than 5 years)

other serious medical conditions, such as: unstable heart disease after treatment, myocardial infarction within 6 months prior to treatment, cardiac function class 3-4 (NYHA); uncontrolled hypertension (\>150/90 mmHg, severe neurological or psychological disorders including dementia or epilepsy) with medical treatment; uncontrolled active infection; acute gastric ulcer; hypercalcemia; chronic obstructive lung disease.

have participated in other clinical studies prior to enrollment.

Note: Positive PSMA PET/CT, defined as based on the miPSMA score scale suggested by the PROMISE Institute (score 0 - below the depth of blood contrast; score 1 - equal to or above the blood contrast and below the liver contrast; score 2 - equal to or above the liver contrast and below the parotid contrast; score 3 - equal to or above the liver parotid contrast.)